What does it take for a breakthrough AI diagnostic tool developed in France or Sweden to gain traction in Boston or Chicago?

The answer lies not just in its algorithms, but in its ability to strategically communicate within the US healthcare system.

Europe is fast becoming a powerhouse for AI-driven healthcare, with innovations emerging from a mix of startups, university spin-outs, and publicly funded research initiatives. As these technologies mature, many face a familiar hurdle: navigating the commercial and regulatory complexities of the United States—still the world’s largest and most competitive healthcare market. From FDA classifications to fragmented reimbursement structures, the transatlantic journey for European MedTech is marked by both opportunity and nuance.

To succeed, European innovators must go beyond clinical excellence. They need to adapt their strategies to the unique demands of the US landscape—aligning with the expectations of regulators, payers, and procurement leaders through targeted communication, robust evidence generation, and AI-driven market intelligence.

Divergent Landscapes: Regulation and Market Expectations

Europe’s approach to AI in healthcare is shaped by a rigorous, ethics-first framework. The EU AI Act, provisionally adopted in 2024, classifies AI systems by risk and imposes strict obligations on high-risk applications—healthcare among them. These rules work in tandem with the EU Medical Device Regulation (MDR), which governs the clinical evaluation, safety, and performance of medical devices and diagnostic technologies. Together, they form a comprehensive but complex compliance environment that prioritises patient safety and data transparency.

In contrast, the US regulatory environment, anchored by the Food and Drug Administration (FDA), favours a more adaptive, iterative model. The FDA has introduced several regulatory pathways for digital health and AI/ML-based medical devices, including:

• 510(k) premarket notification, which allows manufacturers to demonstrate that their device is substantially equivalent to an already approved product. This is often a faster and less costly route to market.
• De Novo classification, designed for novel devices with no direct predicate, enabling innovators to bring first-of-their-kind technologies to market with a reasonable assurance of safety and effectiveness.
• The Breakthrough Devices Program, which offers expedited review for technologies addressing life-threatening or irreversibly debilitating conditions.

Rather than a single overarching regulation like the EU AI Act, the FDA operates through evolving guidance documents and pilot initiatives, such as the AI/ML Software as a Medical Device (SaMD) Action Plan, which supports innovation while focusing on algorithm transparency, real-world performance monitoring, and adaptive learning systems.

While the FDA’s flexible approach can enable faster market access, its lack of harmonisation presents both opportunity and risk. Therefore, European innovators must reframe their compliance narratives to meet US expectations and present a compelling case for both safety and scalability.

AI-Powered Insights to Guide Market Strategy

The complexity of entering the US healthcare market can be mitigated with AI-driven intelligence that maps demand trends, procurement behaviours, and reimbursement models. With the right tools, innovators can uncover patterns in stakeholder adoption, financial viability, and technology uptake timelines to identify:

• US healthcare systems adopting AI diagnostics or robotic surgical systems.
• Reimbursement pathways established by Medicare and private insurers for AI-powered solutions through new CPT (Current Procedural Terminology) codes—the billing codes used by clinicians and hospitals to report medical procedures and services.
• Opportunities where data from routine clinical practice influences formulary listings and hospital technology assessments.

Unlike Europe’s nationally standardised DRG-based reimbursement systems, the US market is highly fragmented—comprising public and private payers, each with distinct coverage policies. Even clinically approved solutions must undergo rigorous economic value assessments before they gain traction.

As the pharmaceutical and biotech landscapes evolve, reliance on list prices has become an increasingly outdated approach. List prices provide a static, oversimplified figure that doesn’t capture the market complexities that companies need to navigate. In today’s environment, net price intelligence—the actual price after all discounts, rebates, and negotiations—provides a more accurate, actionable view of the market. This intelligence is essential for strategic growth and sustainable market access.

The European Union’s Artificial Intelligence Act (AI Act), which came into force on August 1, 2024, marks a groundbreaking move in regulating the application of AI technologies across various industries, with a particular focus on medical technology. With an emphasis on safety, transparency, and adherence to fundamental rights, the legislation sets the framework for how AI systems are developed and used. For the medical technology sector, the AI Act outlines specific obligations that will significantly influence the design and deployment of AI-enabled devices in healthcare.

Implications for the Medical Technology Sector

The AI Act categorises AI systems by risk levels—unacceptable, high, medium, and low. AI-enabled medical devices, given their potential to directly impact patient outcomes, almost invariably fall under the high-risk category. Consequently, manufacturers of these devices must meet rigorous compliance requirements, including the following critical areas:

• Risk Management: Developing comprehensive frameworks to identify, assess, and mitigate risks related to AI-driven components.
• Data Governance: Ensuring that datasets used to train AI systems are high-quality, relevant, diverse, and free of bias to improve reliability and performance.
• Transparency and Documentation: Documenting the AI system’s design, development lifecycle, and decision-making processes in detail to uphold accountability.
• Human Oversight: Incorporating mechanisms to allow human intervention and override AI-driven decisions, safeguarding the central role of human judgment in critical healthcare scenarios.
• Accuracy and Robustness: Demonstrating the reliability, precision, and adaptability of AI systems across various operating conditions.

Beyond these provisions, compliance with the AI Act integrates with the existing requirements of the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR), further heightening the regulatory demands placed on medical technology companies.

Industry’s Response and Actions

The medical technology industry, represented by organisations such as MedTech Europe, recognises the importance of a harmonised regulatory approach and has voiced its support for the EU’s efforts. However, certain challenges remain. MedTech Europe recommends further refinement and clarification to ensure the AI Act not only addresses safety but also encourages innovation and the seamless adoption of AI in healthcare.

Key recommendations include:

• European Commission Guidelines: Advocacy for swift publication of compliance guidelines to provide clear instructions for stakeholders.
• Alignment of Standards: Calls for consistency between the AI Act and existing medical technology standards to eliminate conflicts and redundancy.
• Unified Conformity Assessments: Promotion of consolidated assessment procedures to simplify compliance processes and reduce administrative costs.

Medical device manufacturers are already taking proactive steps to align with the AI Act. Many companies are implementing robust compliance frameworks, which include enhanced quality management systems focusing on risk management, data governance, and human oversight throughout the AI lifecycle. Simultaneously, they are preparing for third-party conformity assessments to meet both AI Act and pre-existing MDR/IVDR obligations.

Challenges and Key Considerations

While the AI Act is a significant milestone, it introduces additional regulatory complexities that could disproportionately impact small and medium-sized enterprises (SMEs) in the medical technology sector. Recognising this, the legislation includes measures such as priority access to regulatory sandboxes and support from European Digital Innovation Hubs to offer SMEs guidance and resources for compliance.

Another key consideration is the increased burden on notified bodies, which conduct conformity assessments. Meeting the requirements of the AI Act necessitates specialised expertise in AI technologies, leading to recruitment challenges, higher operational costs, and potential delays in the approval process.

Looking Ahead

The AI Act is poised to shape the future of AI-enabled medical technology in Europe, setting ethical boundaries and ensuring safety while fostering innovation. Although the additional compliance requirements create challenges, particularly for SMEs, the medical technology industry is actively engaging with regulatory bodies and adapting its practices to meet these demands.

By implementing effective compliance strategies and collaborating with policymakers, the industry aims to integrate AI innovation into healthcare systems while ensuring that patient safety and care quality remain at the forefront of its efforts. The AI Act signals a new era of regulation—one that balances technological advancements with ethical and safety considerations to drive meaningful improvements in European healthcare.

As the medical technology (MedTech) industry navigates 2024, its role as a driving force behind healthcare innovation remains critical. With global revenues now standing at an impressive $587 billion, the industry continues to push boundaries in medical devices, diagnostics, and digital health.

However, while innovation propels the sector forward, it faces significant macroeconomic challenges, including higher costs, constrained financing, and an evolving commercial landscape. According to the latest Pulse of the MedTech Industry report from Ernst & Young LLP (EY US), these dynamics are shaping the future of MedTech, demanding agility, strategic realignment, and a focus on leveraging emerging technologies like artificial intelligence (AI).

The Steady Rise of MedTech: Growth and Innovation

MedTech has seen six consecutive years of topline growth, a testament to its role in reshaping healthcare delivery. In 2023 alone, the sector experienced record FDA approvals, driven by innovative launches in areas such as cardiovascular treatments, robotics, and radiology. This period also marked a significant shift towards AI adoption, with compelling use cases emerging across the value chain—from diagnostics to supply chain management. As the global health landscape becomes increasingly digital, MedTech’s role in integrating AI-powered tools is expanding rapidly.

According to Arda Ural, EY Americas Life Sciences Leader, “MedTechs face several challenges such as increased input costs, tighter reimbursement, and payment pressures from hospital systems.” Despite these challenges, innovation remains the cornerstone of the industry’s success. New technologies that offer more accurate diagnoses, improve surgical outcomes, and reduce the burden on healthcare professionals are expected to drive further growth in 2024 and beyond.

AI and the Future of MedTech

AI is poised to be one of the most transformative forces within the MedTech industry. From enhancing patient outcomes to optimising operational efficiencies, AI-driven solutions are being integrated across the enterprise.

The report highlights five key areas where AI and other advancements are expected to play a pivotal role in shaping the future of MedTech:

• High-Growth Opportunities: Companies are seeking untapped markets, particularly in AI and digital health.
• Cost Optimisation: By leveraging AI, MedTech firms can streamline operations, reducing supply chain inefficiencies and lowering the cost of R&D.
• Revitalised Commercial Models: AI allows MedTechs to build agile, cross-functional teams that can respond in real-time to demand signals, improving the alignment between product offerings and market needs.
• Direct-to-Consumer Engagement: As consumers become more involved in managing their health, AI-driven platforms provide personalised, data-driven healthcare experiences.
• Strategic Portfolio Management: AI tools help companies refine their portfolios by identifying high-value areas for investment or divestiture, positioning them for long-term growth.

Jim Welch, EY Global MedTech Leader, noted that “a better commercial model execution will be integral to building the company’s topline” as companies face increasing pressure from both regulators and customers to adapt to the changing landscape. The successful integration of AI and new commercial strategies will separate the leaders from the rest of the pack.

Qatar is on the brink of a significant transformation in its healthcare sector, with a substantial rise in demand for advanced medical equipment anticipated in the coming years. This expected surge is driven by a combination of strategic initiatives, demographic changes, and technological advancements, all aimed at positioning Qatar as a regional leader in healthcare.

A Healthcare Sector on the Rise

Qatar’s healthcare sector is experiencing unprecedented growth, fuelled by government investments, strategic planning, and an increasing demand for high-quality medical services. By 2024, the market is expected to reach $12 billion, a substantial increase driven by Qatar’s National Vision 2030, a long-term strategy aimed at diversifying the economy away from oil dependency by investing heavily in sectors like healthcare.

The Qatari government has prioritised healthcare as a key pillar of its national development strategy. This commitment is reflected in substantial budget allocations for healthcare, which have been used to build and expand state-of-the-art hospitals, clinics, and research facilities. Notably, Hamad Medical Corporation, the largest healthcare provider in Qatar, has expanded its network to include 16 hospitals, while the Primary Health Care Corporation operates 33 health centres across the country.

Moreover, the healthcare sector’s growth is also being driven by the government’s push to make Qatar a regional hub for medical tourism. With the construction of world-class medical facilities, Qatar is positioning itself to attract patients from across the Middle East and beyond. The country’s visa-free access to over 80 countries, coupled with its advanced healthcare services, makes it an attractive destination for medical tourists seeking high-quality care.

In addition to infrastructure, Qatar is also focusing on training and retaining top medical professionals. This includes partnerships with leading global institutions and the establishment of educational programs aimed at producing highly skilled healthcare workers. The result is a healthcare system that not only meets the needs of its domestic population but also has the capacity to serve international patients, further driving demand for advanced medical technologies.